Abstract:AMPK activation appears in a healthy liver during fasting in response to energy generation needs. AMPK enhances FA oxidation and autophagy, reducing lipid accumulation. mTORC1 activation occurs in high food intake in a diseased liver, leading to lipogenesis, reducing FA oxidation, lipolysis, and autophagy, leading to liver lipid accumulation and NAFLD. ACC2, acetyl‐Coa carboxylase 2; AKT, protein kinase B; AMPK, AMP‐activated protein kinase; CPT1, carnitine palmitoyl transferase I; DNL, de novo lipogenesis; FA, fatty acid; GTP, GTPase‐activating protein; HSL, hormone‐sensitive lipase; IR, insulin receptor; LKB, liver kinase B; mTOR, mechanistic target of rapamycin; NAFLD, non‐alcoholic fatty liver disease; PGC‐1α, peroxisome proliferator‐activated receptor‐gamma coactivator‐1 alpha; PI3K, phosphoinositide 3‐ kinase; PPARa, peroxisome proliferator‐activated receptors alpha; RHEB, Ras homolog enriched in the brain; TSC, tuberous sclerosis complex; ULK1, unc‐51‐like kinase 1. Obesity is related to several organs, but the liver is particularly affected. Adenosine monophosphate‐activated protein kinase (AMPK) is a cellular energy sensor and regulator of liver lipid dysfunction and glucose metabolism. The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Together, these pathways are involved in obesity, insulin resistance, non‐alcoholic fatty liver disease (NAFLD) and its progression, and autophagy. During energy demand, liver kinase B (LKB) phosphorylation helps activate the AMPK/mTOR pathways. Likewise, the protein forkhead box O family (FOXO) negatively regulates adipogenesis by binding to the promoter sites of peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha, initiating adipogenesis. In addition, acetyl‐CoA carboxylase, which regulates de novo lipogenesis, is linked to LKB and FOXO in developing NAFLD. The kinase complex, consisting of Unc‐51‐like autophagy‐activating kinase 1 or 2 (ULK1, ULK2) by stimulating autophagy, and eliminating fat droplets in NAFLD, is regulated by mTORC1 and negatively regulated by AMPK that suppresses liver lipogenesis and increases fatty acid oxidation. Also, ULK1 is essential for initiating phagophore formation, establishing macrophagy, and generating autophagosomes. The selective breakdown of lipid droplets through macroautophagy, or macrolipophagy, occurs on a cellular energy level using free fatty acids. In addition, mTORC1 promotes lipogenesis by activating sterol regulatory element‐binding protein. Finding new components and novel regulatory modes in signaling is significant for a better understanding of the AMPK/mTOR pathways, potentially facilitating the development of future diagnostic and therapeutic strategies for NAFLD and its progression to non‐alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.

From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis

The Role of AMPKα2 in the HFD-induced Nonalcoholic Steatohepatitis.

The AMPK pathway in fatty liver disease

Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD

AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression

Crosstalk of 5′-Monophosphate-Activated Protein Kinase (AMPK) with Extracellular and Intracellular Signaling Pathways in the Regulation of Nutrient Metabolism and Cell Survival in the Liver

Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products

The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

SLC7A11-ROS/αKG-AMPK axis regulates liver inflammation through mitophagy and impairs liver fibrosis and NASH progression

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions

A double-edged sword: The Kelch-like ECH-associated protein 1-nuclear factor erythroid-derived 2-related factor 2-antioxidant response element pathway targeted pharmacological modulation in nonalcoholic fatty liver disease

Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis

Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis